Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors

We hypothesized that the number of tumor infiltrating cytotoxic T-cells (CTCs) and regulatory T-cells (Tregs), shown to have prognostic value in other lymphoproliferative disorders, could predict survival in post-transplant lymphoproliferative disorder (PTLD). Sixty-two patients were diagnosed with PTLD between 1987 and 2007, with 44 cases representing monomorphic B-cell PTLDs with diffuse aggressive morphologic features. Of these 44 cases, 31 had sufficient tissue for further study. On univariate analysis, high tumor infiltrating CD3+ T-cell (≥550/10 hpf) and TIA-1+ CTC (≥300/10 hpf) counts were associated with favorable overall survival (OS), PTLD-specific survival (PTLD-SS), and progression-free survival (PFS) while Treg counts were not predictive of outcome. However, on multivariate analysis, clinical factors were the most powerful predictor of PTLD outcome (performance status and CHOP as first line therapy for OS; performance status and number of extranodal sites for both PTLD-SS and PFS).

[1]  L. Szekely,et al.  NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  M. Hattori,et al.  Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients. , 2008, Clinical nephrology.

[3]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[4]  T. Kelley,et al.  The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. , 2007, American journal of clinical pathology.

[5]  G. Salles,et al.  Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?. , 2007 .

[6]  E. Hsi,et al.  The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. , 2007, Archives of pathology & laboratory medicine.

[7]  K. Faber,et al.  Effects of different immunosuppressive regimens on regulatory T‐cells in noninflamed colon of liver transplant recipients , 2007, Inflammatory bowel diseases.

[8]  B. Dörken,et al.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.

[9]  H. Nilsson‐Ehle,et al.  The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma , 2007, British journal of haematology.

[10]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Horning,et al.  Mature Results of a Prospective Trial of Rituximab in Patients (Pt) with Post Transplant Lymphoproliferative Disorder (PTLD) Unresponsive or Ineligible for Reduced Immunosuppression (RIS). , 2006 .

[12]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[13]  B. Moulin,et al.  Post‐Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Irene Ghobrial,et al.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. , 2006, Blood.

[15]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[16]  G. Grabenbauer,et al.  Tumor-Infiltrating Cytotoxic T Cells but not Regulatory T Cells Predict Outcome in Anal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[17]  E. Shevach,et al.  Activated CD4+CD25+ T cells selectively kill B lymphocytes. , 2006, Blood.

[18]  T. Habermann,et al.  Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  G. Salles,et al.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.

[20]  K. Olthoff,et al.  Treatment of PTLD with Rituximab or Chemotherapy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  C. Canter,et al.  Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study , 2006, The Lancet.

[22]  R. Kandaswamy,et al.  Posttransplant Lymphoproliferative Disorder in Pancreas Transplantation: A Single-Center Experience , 2005, Transplantation.

[23]  R. Alloway,et al.  Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. , 2005, Transplantation proceedings.

[24]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[25]  T. Habermann,et al.  Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era , 2005, Leukemia & lymphoma.

[26]  E. Haddad,et al.  RELATIONSHIP BETWEEN CD8+ T-CELL PHENOTYPE AND FUNCTION, EPSTEIN-BARR VIRUS LOAD, AND CLINICAL OUTCOME IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY1 , 2004, Transplantation.

[27]  G. Opelz,et al.  Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  M. Steele,et al.  Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. , 2003, Chest.

[29]  S. Hamilton-Dutoit,et al.  Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? , 2003, Transplantation.

[30]  R. Hornung,et al.  Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment , 2003, Transplantation.

[31]  G. Mazariegos,et al.  Posttransplant Lymphoproliferative Disorders in Liver Transplantation: A 20-Year Experience , 2002, Annals of surgery.

[32]  E. Yakirevich,et al.  Activated status of tumour‐infiltrating lymphocytes and apoptosis in testicular seminoma , 2002, The Journal of pathology.

[33]  D. Wigle,et al.  Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. , 2001, Transplantation.

[34]  S. Cockfield Identifying the patient at risk for post‐transplant lymphoproliferative disorder , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[35]  R. Porcher,et al.  Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Tsurumi,et al.  Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. , 2000, The Journal of infectious diseases.

[37]  M. DeBaun,et al.  High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. , 2000, American journal of respiratory and critical care medicine.

[38]  M. Yacoub,et al.  Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus. , 2000, Transplantation.

[39]  S. Swerdlow,et al.  Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? , 2000, The American journal of surgical pathology.

[40]  T. Whiteside,et al.  Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. , 1999, Leukemia & lymphoma.

[41]  G. Rennert,et al.  Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[42]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[43]  P. Gaulard,et al.  Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation , 1999, Hepatology.

[44]  T. Starzl,et al.  Cytokine mRNA profiles in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders , 1999, Clinical transplantation.

[45]  J. Thistlethwaite,et al.  Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. , 1997, The Journal of pediatrics.

[46]  M. Yacoub,et al.  Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. , 1996, The Journal of general virology.

[47]  F. Davi,et al.  Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Fisher,et al.  Aggressive treatment for postcardiac transplant lymphoproliferation. , 1995, Blood.

[49]  W. Weimar,et al.  Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load , 1992, Transplant international : official journal of the European Society for Organ Transplantation.

[50]  V. Godfrey,et al.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.

[51]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[52]  T. Beveridge,et al.  LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY , 1984, The Lancet.

[53]  T. Starzl,et al.  REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.

[54]  D. Titterington,et al.  INFLUENCE OF HLA MATCHING AND BLOOD TRANSFUSION ON RENAL ALLOGRAFT SURVIVAL , 1978, Transplantation.

[55]  J. H. Harrison,et al.  Five Years' Experience in Renal Transplantation with Immunosuppressive Drugs: Survival, Function, Complications, and the Role of Lymphocyte Depletion by Thoracic Duct Fistula , 1968, Annals of surgery.

[56]  T. Starzl,et al.  Orthotopic homotransplantation of the human liver. , 1968 .

[57]  V. Levitsky,et al.  The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. , 2006, Haematologica.

[58]  B. Sander,et al.  Posttransplant lymphoma—A single-center experience of 500 liver transplantations , 2004, Medical oncology.

[59]  T. Habermann,et al.  Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.